## First-Trimester Screening Interpretation ### Dating Discrepancy & NT Findings **Key Point:** This case presents **two concerning findings:** 1. **Significant dating discrepancy:** 2 weeks + 3 days (LMP 13+5 vs. ultrasound 11+2) 2. **Elevated nuchal translucency:** 3.2 mm at 11–12 weeks (normal <2.5 mm) **High-Yield:** A dating discrepancy of >2 weeks in the first trimester, combined with elevated NT, raises suspicion for **chromosomal abnormality** (trisomy 21, 18, 13) or **congenital heart disease**. ## Risk Stratification Framework ```mermaid flowchart TD A["First-trimester screening<br/>CRL + NT + serum markers"]:::outcome A --> B{"Dating discrepancy?<br/>& NT elevated?"}:::decision B -->|"Yes (as in this case)"|C["Increased aneuploidy risk<br/>Reassess dating by CRL"]:::outcome C --> D{"Offer invasive testing?"}:::decision D -->|"High risk / parental choice"|E["Amniocentesis<br/>or CVS"]:::action D -->|"Intermediate risk"|F["cfDNA testing<br/>+ detailed anatomy scan"]:::action D -->|"Declining invasive"|G["Serial ultrasound<br/>Fetal echocardiography"]:::action F --> H["Reassurance or<br/>further counseling"]:::outcome E --> I["Karyotype result<br/>Prognostic counseling"]:::outcome ``` ## Why cfDNA + Detailed Anatomy Scan? ### cfDNA Testing (Cell-Free Fetal DNA / NIPT) **Clinical Pearl:** cfDNA testing is the **most appropriate first-line non-invasive test** for aneuploidy risk stratification when first-trimester screening is abnormal: | Feature | cfDNA | |---------|-------| | **Detection rate (Trisomy 21)** | 99% | | **False-positive rate** | <0.1% | | **Timing** | Can be done now (>10 weeks) | | **Invasiveness** | Non-invasive (maternal blood) | | **Turnaround** | 7–10 days | **Key Point:** cfDNA is superior to first-trimester combined screening (CRL + NT + serum markers) in this scenario because: - The dating discrepancy makes serum marker interpretation unreliable (markers are gestational-age-dependent) - cfDNA is not affected by dating errors - It provides a definitive risk assessment without invasive testing ### Detailed Second-Trimester Anatomy Scan (20 weeks) **High-Yield:** The anatomy scan serves multiple purposes: 1. **Soft markers for aneuploidy:** Echogenic intracardiac focus, choroid plexus cyst, renal pyelectasis, short femur 2. **Cardiac assessment:** Rule out congenital heart disease (associated with elevated NT) 3. **Re-dating:** Confirm gestational age; if dating is now consistent with LMP, aneuploidy risk may be lower 4. **Reassurance:** Many fetuses with elevated NT have normal outcomes ## Why Other Options Are Suboptimal ### Option 0: Reassurance & Accept LMP Dating **Warning:** This is a dangerous approach. A 2+ week discrepancy in the first trimester is **not normal variation** — it suggests either: - Incorrect LMP dating (ovulation/conception later than expected) - Intrauterine growth restriction (IUGR) or chromosomal abnormality The **CRL is the most accurate dating method** in the first trimester (±3–5 days). The ultrasound dating should be accepted, and the elevated NT must be investigated. ### Option 2: Immediate Amniocentesis **Clinical Pearl:** While amniocentesis is definitive, it carries a small but real risk of miscarriage (~0.1–0.3%). Given that cfDNA can provide nearly equivalent diagnostic accuracy **non-invasively**, amniocentesis should be reserved for: - High-risk cfDNA results - Parental preference for definitive diagnosis - Specific fetal anomalies on ultrasound Immediate amniocentesis without first offering cfDNA is not standard of care and bypasses a safer, first-line test. ### Option 3: Termination of Pregnancy **Warning:** This is premature and inappropriate. Elevated NT alone does NOT predict lethality: - ~70–80% of fetuses with isolated elevated NT have normal karyotype - Even with trisomy 21, many children have good quality of life - Prognosis requires complete information: cfDNA result, anatomy scan findings, parental values Termination without offering testing and counseling violates informed consent principles. ## Counseling Points **Mnemonic: CFDA (Cell-Free DNA Algorithm)** - **C**onfirm dating by CRL (accept ultrasound dating) - **F**irst-line: cfDNA testing (non-invasive, high accuracy) - **D**etailed anatomy scan at 20 weeks (soft markers, cardiac assessment) - **A**mniocentesis only if high-risk cfDNA or fetal anomalies [cite:ACOG Practice Bulletin 226; ISUOG Guidelines 2013; Callen Obstetric Ultrasound Ch 5] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.